Letter | Published:

An elaborate pathway required for Ras-mediated epigenetic silencing

Nature volume 449, pages 10731077 (25 October 2007) | Download Citation


The conversion of a normal cell to a cancer cell occurs in several steps and typically involves the activation of oncogenes and the inactivation of tumour suppressor and pro-apoptotic genes1. In many instances, inactivation of genes critical for cancer development occurs by epigenetic silencing, often involving hypermethylation of CpG-rich promoter regions2,3. It remains to be determined whether silencing occurs by random acquisition of epigenetic marks that confer a selective growth advantage or through a specific pathway initiated by an oncogene4,5,6. Here we perform a genome-wide RNA interference (RNAi) screen in K-ras-transformed NIH 3T3 cells and identify 28 genes required for Ras-mediated epigenetic silencing of the pro-apoptotic Fas gene. At least nine of these RESEs (Ras epigenetic silencing effectors), including the DNA methyltransferase DNMT1, are directly associated with specific regions of the Fas promoter in K-ras-transformed NIH 3T3 cells but not in untransformed NIH 3T3 cells. RNAi-mediated knockdown of any of the 28 RESEs results in failure to recruit DNMT1 to the Fas promoter, loss of Fas promoter hypermethylation, and derepression of Fas expression. Analysis of five other epigenetically repressed genes indicates that Ras directs the silencing of multiple unrelated genes through a largely common pathway. Last, we show that nine RESEs are required for anchorage-independent growth and tumorigenicity of K-ras-transformed NIH 3T3 cells; these nine genes have not previously been implicated in transformation by Ras. Our results show that Ras-mediated epigenetic silencing occurs through a specific, complex, pathway involving components that are required for maintenance of a fully transformed phenotype.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    & The hallmarks of cancer. Cell 100, 57–70 (2000)

  2. 2.

    DNA methylation and gene silencing in cancer. Nature Clin. Pract. Oncol. 2 (Suppl. 1). S4–S11 (2005)

  3. 3.

    Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br. J. Cancer 94, 179–183 (2006)

  4. 4.

    DNA methylation errors and cancer. Cancer Res. 56, 2463–2467 (1996)

  5. 5.

    & Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1, 299–305 (2002)

  6. 6.

    et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nature Genet. 38, 149–153 (2006)

  7. 7.

    Oncogenic Ras in tumour progression and metastasis. Biol. Chem. 386, 193–205 (2005)

  8. 8.

    et al. Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations. Leuk. Lymphoma 47, 1387–1391 (2006)

  9. 9.

    , , , & Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras. Cancer Res. 58, 3391–3400 (1998)

  10. 10.

    et al. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J. 18, 1824–1831 (1999)

  11. 11.

    , & PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9, 667–676 (2004)

  12. 12.

    , , , & Involvement of p21ras in activation of extracellular signal-regulated kinase 2. Nature 357, 602–604 (1992)

  13. 13.

    et al. Proteomic analysis of p38α mitogen-activated protein kinase-regulated changes in membrane fractions of RAS-transformed fibroblasts. Proteomics 6 (Suppl 1). S262–S271 (2006)

  14. 14.

    et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nature Genet. 39, 237–242 (2007)

  15. 15.

    et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nature Genet. 39, 232–236 (2007)

  16. 16.

    et al. Epigenetic stem cell signature in cancer. Nature Genet. 39, 157–158 (2007)

  17. 17.

    , & The chromatin remodeling complex NoRC targets HDAC1 to the ribosomal gene promoter and represses RNA polymerase I transcription. EMBO J. 21, 4632–4640 (2002)

  18. 18.

    et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genet. 37, 853–862 (2005)

  19. 19.

    , , & Secreted WNT antagonists as tumor suppressors: pro and con. Front. Biosci. 11, 2093–2105 (2006)

  20. 20.

    & Regulation of cancer cell survival by Par-4. Ann. NY Acad. Sci. 1059, 76–85 (2005)

  21. 21.

    LOT1 (ZAC1/PLAGL1) and its family members: mechanisms and functions. J. Cell. Physiol. 210, 16–25 (2007)

  22. 22.

    et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 22, 1615–1623 (2001)

  23. 23.

    et al. Lysyl oxidase and rrg messenger RNA. Science 253, 802 (1991)

  24. 24.

    et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA 89, 1827–1831 (1992)

  25. 25.

    A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001)

Download references


We thank S. Evans for editorial assistance. C.G. is on leave from the CNRS, Paris, France. This work was funded in part by a grant from the NIH to M.R.G. M.R.G. is an investigator of the Howard Hughes Medical Institute.

Author Contributions S.G. and C.-M.V. prepared the retroviral library. C.G. and N.W. performed all experiments and data analyses. C.G., N.W. and M.R.G. designed the experiments, discussed the interpretation of the results and co-wrote the paper. All authors commented on the manuscript.

Author information

Author notes

    • Claude Gazin
    •  & Narendra Wajapeyee

    These authors contributed equally to this work.


  1. Howard Hughes Medical Institute and Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, USA

    • Claude Gazin
    • , Narendra Wajapeyee
    • , Stephane Gobeil
    • , Ching-Man Virbasius
    •  & Michael R. Green


  1. Search for Claude Gazin in:

  2. Search for Narendra Wajapeyee in:

  3. Search for Stephane Gobeil in:

  4. Search for Ching-Man Virbasius in:

  5. Search for Michael R. Green in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Michael R. Green.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    The file contains Supplementary Figures 1-12 and Supplementary Tables 1-2 with Legends; Supplementary Methods and additional references.  The Supplementary Figures show several control experiments; confirm and extend the generality of Fas silencing and the involvement of RESEs to other mouse and human ras-transformed cell lines; show transcriptional or post-transcriptional upregulation of several RESEs by Ras; confirm the hypermethylated status of additional promoters; and show the requirement for several RESEs for a fully transformed phenotype. The Supplementary Tables provide shRNA and primer sequence information, as well as supplementary methods and references.

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.